Sign in
Not yet recruitingPhase 2

Study to Investigate the Efficacy and Safety of Apomivir®

Key facts

Who runs it
Far East Bio-Tec Co., Ltd
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
196 people, planned
Started
31 May 2026
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Apomivir®
  • Placebo
Record updated
14 May 2025

Who can take part

Age
20 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Other criteria

  • Main inclusion criteria:
  • Females and males aged between 20 and 65
  • Presumptive diagnosis of influenza based on the following clinical characteristics:; Present at least one respiratory symptom (e.g. cough, nasal obstruction, sore throat) and at least one constitutional symptom other than fever (e.g. fatigue, headache, myalgias) of less than 48-hour duration; Positive for influenza A or B (nasopharyngeal/throat swab - rapid test)
  • Able and willing to comply with the study procedure and give written informed consent
  • Main exclusion criteria:
  • Female who is pregnant/lactating or planning to be pregnant, or female of childbearing potential* who is not using medically recognized method of contraception; Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal
  • Subject with chronic pulmonary diseases or critical condition or already developed severe respiratory distress with hypoxaemia on presentation
  • Subject with a history of non-febrile convulsions, neuromuscular disorders or cognitive dysfunction that may compromise respiratory secretions, or who are currently receiving anticonvulsive agents
  • Subject with clinically important illness, malignancies, systemic infection, other medical or psychiatric condition which places the subject at unacceptable risk to participate in the study or confounds the ability to interpret data from the study
  • Subject with significant abnormal laboratory findings (hemoglobin level < 9.0 g/dL, WBC < 4000/mm3, platelet count < 100,000/mm3, ALT or AST > 2.5 x upper limit of normal (ULN), or estimated creatinine clearance < 30 mL/min within 4 weeks prior to baseline)
  • Subject who are currently receiving immunosuppressive therapy,
  • Subject has taken daily supplement(s) containing blue agar within 1 month prior to screening, or any other medication that may affect the study results
  • Known hypersensitivity to any ingredients in Apomivir® or other blue agar
  • Use of any investigational product within 1 month prior to screening

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 20 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Apomivir® is extracted from a proprietary spirulina strain, FEM-101, a kind of blue cyanobacterium with patented freeze-thaw lysis and extraction method. According to the preclinical studies, Apomivir® have been proven to have excellent broad-spectrum anti-viral ability, especially for seasonal influenza viruses (Influenza virus A and B) that may cause illness, paralysis and even death, especially in children and elderly people. This phase II study is designed to evaluate the efficacy and safety of Apomivir® (120 mg b.i.d.) in subjects with seasonal influenza.

The 2 groups in the trial

  • Control GroupPlacebo, for comparison

    Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal

    Treatment: Placebo

  • Study GroupTreatment being tested

    Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.

    Treatment: Apomivir®

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Apomivir® in Relieving Influenza Symptoms
Criteria questions
Built from NCT01677689, who can take part
Record updated
14 May 2025